BioCentury
ARTICLE | Company News

Lee's mulls spin off, HK IPO for China oncology subsidiary

July 27, 2018 5:22 PM UTC

Lee's Pharmaceutical Holdings Ltd. (HKSE:950) said it will consolidate its oncology development pipeline into its China Oncology Focus Ltd. (COF) subsidiary. Lee's CFO Jason Chow told BioCentury that the company expects the reorganization to potentiate COF's possible spin out and listing on Hong Kong Exchanges and Clearing Ltd. (HKEX).

Chow said Lee's is evaluating the feasibility of such a spin out and will update shareholders and investors "as soon as possible."...